Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07664007
NA

Effects of EPA Supplementation on Patients With Unresectable Hepatocellular Carcinoma.

Sponsor: Instituto de Investigación Sanitaria Aragón

View on ClinicalTrials.gov

Summary

Dietary intervention with eicosapentaenoic acid combined with chemotherapy may shift inflammatory mediators toward resolution in non-resectable hepatocarcinoma and help to preserve muscle mass.

Official title: Effects of Nutritional Supplementation With Eicosapentaenoic Acid (EPA) on Body Composition and Systemic Pro-inflammatory and Pro-resolving Mediators in Patients Diagnosed With Unresectable Hepatocellular Carcinoma.

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

18

Start Date

2019-03-04

Completion Date

2025-06-20

Last Updated

2026-06-23

Healthy Volunteers

No

Interventions

DIETARY_SUPPLEMENT

Eicosapentaenoic acid oral lipidic emulsion

1 sachet/day of 20 ml containing 3g EPA during 12 weeks

DIETARY_SUPPLEMENT

Pacebo oral lipidic emulsion

1 sachet/day of 20 ml of placebo during 12 weeks

Locations (1)

Hospital Clínico Universitario Lozano Blesa. IIS Aragón

Zaragoza, Zaragoza, Spain